Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multi-center, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Liquid Certolizumab Pegol as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and in the Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Participated in Study CDP870-050

NCT00160641 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00160641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00160641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multi-center, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Liquid Certolizumab Pegol as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and in the Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Participated in Study CDP870-050
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2005
Completion date
February 29, 2012
Enrollment
567 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis